<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...

    Arena Pharmaceuticals is driven to deliver nove...

    Filing Type:    PU
    Otsuka Holdings Co. Ltd.

    Otsuka Holdings Co. Ltd.

    Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...

    Otsuka Holdings Co Ltd is a pharmaceutical comp...

    Filing Type:    PU
    Illusio, Inc.

    Illusio, Inc.

    ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...

    ILLUSIO is a plastic surgery simulation tool th...

    Fundraising Status:    EC
    Filing Type:    CF
    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...

    Nemucore Medical Innovations is here to bring y...

    Amount Raised:    $92,318.00
    Fundraising Status:    EC
    Filing Type:    CF
    Anchiano Therapeutics Ltd.

    Anchiano Therapeutics Ltd.

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...

    We are Anchiano Therapeutics, a pivotal-stage b...

    Filing Type:    PU
    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...

    BioDelivery Sciences International, Inc. (NASDA...

    Filing Type:    PU
    Regeneron Pharmaceuticals, Inc.

    Regeneron Pharmaceuticals, Inc.

    We are a leading science and technology company that delivers life-transforming me...

    We are a leading science and technology company...

    Filing Type:    PU
    Erytech Pharma S.A.

    Erytech Pharma S.A.

    Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...

    Founded in Lyon, France in 2004, ERYTECH is a c...

    Filing Type:    PU
    Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...

    Aptevo Therapeutics Inc. is a clinical-stage bi...

    Filing Type:    PU
    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    Provention Bio, Inc.

    Provention Bio, Inc.

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...

    Provention Bio, Inc. is a clinical-stage biopha...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.